Novo Nordisk's India Insulin Push and 15 Billion Kroner Buyback Jointly Propel Shares Off Lows
Published on 07/12/2026 at 21:13 | Redaktion boerse-global.de
Novo Nordisk is leaning on two very different levers to regain its footing. The Danish pharmaceutical giant is rolling out its once-weekly basal insulin Awiqli in India at a fraction of the cost of daily alternatives, while simultaneously executing a massive share buyback that has absorbed more than 6 billion kroner in stock since early February. The combination has helped the B-shares recover more than 43% from their March 2026 low of €30.25, closing Friday at €43.32 — a gain of 1.29% on the day.
The India launch marks the seventh market for Awiqli, the world's first weekly basal insulin. Novo Nordisk is pricing the drug aggressively to penetrate a population where over 101 million people live with diabetes, yet only about 6 million currently receive insulin therapy. A weekly dose of 70 units costs roughly $3.07, compared with $4.06 to $5.33 for daily basal insulins. The product is available in two pen formats: a 1-mL pen (700 units) for $30.72 and a 3-mL pen (2,100 units) for $92.15. Vikrant Shrotriya, Novo Nordisk's India head, said at the New Delhi launch that the company expects the number of patients on insulin in the country to climb to 9 million as more people transition from oral medications, which they now take for an average of seven to nine years before starting insulin.
Back in Copenhagen, the share price is also benefiting from a mechanical tailwind. On February 4, 2026, Novo Nordisk announced a 12-month program to buy back up to 15 billion Danish kroner of its B-shares. As of July 3, the company had repurchased just over 23 million shares at an average price of 270.32 kroner each, spending roughly 6.2 billion kroner. That brings its total treasury holding to 40,194,480 B-shares, or 0.9% of the combined A- and B-share capital. The near-daily purchases are viewed by market participants as a technical support that has helped sustain the recovery from the March trough.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The rebound, however, remains fragile. Despite the 30-day surge of 16.78%, the stock is still down 3.04% year-to-date and has lost 29.22% over the past twelve months. At €43.32, it trades more than 29% below its 52-week high of €61.20 from July 2025. The current price sits comfortably above both the 50-day moving average of €39.51 and the 200-day line of €40.60, but the 14-day relative strength index of 66 signals the stock is approaching overbought territory. Annualized 30-day volatility stands at 30.23%, underscoring persistent sensitivity to news flow around obesity and diabetes.
Analyst views on the sustainability of the rally are split. HSBC lifted its target price to 300 kroner from 280 in early July, and Nordea upgraded the stock from Hold to Buy in June. But J.P. Morgan and Deutsche Bank have kept their Hold ratings unchanged. The divergence highlights a central question: how much of the recent move reflects genuine fundamental improvement versus short-covering and buyback-driven demand.
On the pipeline front, the company suffered a setback when a Phase 2 study comparing two injector variants of the obesity drug CagriSema was marked as withdrawn on ClinicalTrials.gov in early July. Smaller early-stage trials, including a dose-escalation study for an experimental obesity compound, continue to move forward. The broader metabolic pipeline remains active even as competition from Eli Lilly's Zepbound and Mounjaro franchise intensifies.
The next major catalyst arrives on August 5, when Novo Nordisk reports first-half earnings before the market opens. Investors will be looking for updated revenue guidance for the obesity business, details on U.S. sales of the oral Wegovy tablet, and management's assessment of the competitive landscape. Until then, the daily rhythm of the buyback and the gradual build-out of Awiqli in India are likely to provide the primary narrative for a stock still climbing back from a deep drawdown.
Ad
Novo Nordisk Stock: New Analysis - 12 July
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
